Nicolas Girard

Nicolas Girard, MD, PhD, is Head of Medical Oncology at Institut Curie in Paris and Professor of Thoracic Oncology at Université Paris Saclay. He is a leading French thoracic oncologist with particular expertise in the design and conduct of first-line combination immunotherapy trials in NSCLC, including the IMpower150 program evaluating atezolizumab plus bevacizumab plus carboplatin plus paclitaxel (ABCP regimen) in metastatic NSCLC. IMpower150 was a landmark trial demonstrating that the ABCP quadruplet regimen significantly improved PFS and OS compared to chemotherapy plus bevacizumab or atezolizumab plus chemotherapy, with particularly notable benefit in EGFR/ALK-altered NSCLC patients who had progressed on targeted therapy—a population typically excluded from immunotherapy trials. Girard has extensive experience with molecular profiling of NSCLC and has contributed to European guidelines on biomarker-driven treatment selection. He also leads one of Europe's foremost programs on thymic epithelial tumors, a rare thoracic malignancy with distinct immunological features including paraneoplastic syndromes and autoimmune toxicities that complicate immunotherapy use. His translational research intersects computational pathology, liquid biopsy, and immune profiling to predict immunotherapy benefit and toxicity in thoracic cancers. Girard is a frequent invited faculty member at ESMO, ASCO, and IASLC congresses.